INAD Active · Pilot Field Study Initiating · Updated July 7, 2026
Akston AKS-562c: INAD Filed, Pilot Field Study Initiated in Cats
AKS-562c has an active Investigational New Animal Drug (INAD) designation with FDA-CVM and is now initiating a pilot field safety and effectiveness study in client-owned cats: a significant regulatory step beyond the Cornell lab-setting trial and the ACVIM Forum safety presentation. Separately, Akston is developing a canine-specific version of AKS-562c, making it the first dual-species GLP-1 program in veterinary pharma. We're tracking the full regulatory path to approval.
10 min read·Updated July 7, 2026·By Iacob Pastina
How will pet GLP-1 be priced and distributed?What is known, what is estimated, and when you can actually get it. See the pricing & availability breakdown.→Status: July 7, 2026 · INAD active with FDA-CVM · Pilot field study initiating · Canine program announcedAKS-562c now has an active Investigational New Animal Drug (INAD) designation with the FDA Center for Veterinary Medicine and is initiating a pilot field safety and effectiveness study in client-owned cats: representing a material regulatory advancement beyond the Cornell lab-setting trial. This is the formal FDA-CVM gateway: an INAD permits clinical investigation under agency oversight, and a pilot field study tests both safety and effectiveness in real-world veterinary practice settings ahead of any pivotal study. Separately, Akston has disclosed development of a canine-specific version of AKS-562c (per SEC S-1/A filing and dvm360), making it the first dual-species GLP-1 program in veterinary pharma. ACVIM Forum safety data (June 2026) remains the last public efficacy signal, full weight/BCS readout is still pending. We continue monitoring AXTN EDGAR filings, Cornell research pages, and dvm360 / Veterinary Practice News.
Update: July 7, 2026 · INAD Active + Pilot Field Study InitiatedAkston Biosciences has disclosed that AKS-562c carries an active INAD (Investigational New Animal Drug) with FDA-CVM and is now initiating a pilot field safety and effectiveness study in client-owned cats. This is a significant step beyond what was presented at ACVIM Forum in June 2026 (12-week safety/tolerability data in a controlled Cornell setting). A pilot field study is conducted at real veterinary practices with client-owned animals under normal clinical conditions. It tests both safety AND effectiveness, whereas the Cornell trial was focused on the initial safety read. Under FDA-CVM's conditional approval pathway (the same framework Loyal Pharma used for LOY-002), a successful pilot field study is typically followed by a pivotal effectiveness study or a conditional approval application. Sources: dvm360, Cornell University College of Veterinary Medicine study page.
Update: July 7, 2026 · Akston Developing Canine-Specific AKS-562cAkston Biosciences is developing a canine-specific version of AKS-562c: a once-weekly GLP-1 Fc-fusion injection targeting dog obesity. This makes Akston the first company with a disclosed dual-species GLP-1 program in veterinary pharma: AKS-562c in cats (INAD active, pilot field study initiating) and an early-stage canine variant in parallel development. No clinical trial timeline for the canine variant has been publicly announced as of July 2026. Sources: Akston Biosciences SEC S-1/A filing, dvm360.
Update: June 2026 · ACVIM Forum: AKS-562c 12-Week Safety Data PresentedAkston Biosciences presented AKS-562c 12-week safety and tolerability data at the 2026 ACVIM (American College of Veterinary Internal Medicine) Forum. Key findings: AKS-562c was well-tolerated in felines across the Cornell cohort, with no treatment-related toxicity observed and no antidrug antibodies detected. The absence of antidrug antibodies is specifically important for the Fc-fusion platform. It confirms the molecule does not trigger immune responses that would render repeated dosing ineffective over time. This is the first publicly presented safety dataset for a once-weekly injectable GLP-1 receptor agonist in cats. Source: dvm360 ACVIM Forum coverage. Note: Full efficacy data, weight loss percentage and Body Condition Score shift, was not presented at ACVIM. That disclosure remains pending.
Update: May 2, 2026 · Akston files S-1 IPOAkston Biosciences filed an S-1 for a $20M IPO at approximately $100M market capitalization, listing under ticker AXTN on NYSE American. The filing makes Akston a public company with mandatory financial disclosure: a meaningful credibility signal for the Cornell AKS-562c cat GLP-1 trial. The S-1 lists AKS-701d (canine bladder cancer) as the lead product and AKS-562c (cat GLP-1) in the disclosed pipeline. Cornell trial results remain unpublished.
Update: Mid-May 2026 · S-1/A Amendment #30 + Free Writing Prospectus, Roadshow Confirmed ActiveAkston filed S-1/A amendment #30 and a companion Free Writing Prospectus (FWP) simultaneously in mid-May 2026: the standard SEC filing pair that confirms an IPO roadshow is actively underway (institutional investor meetings are in progress). This is a significant milestone: the roadshow proceeding means Akston and underwriter ThinkEquity believe the offering is marketable at the $8-10/share range. Critically: the S-1/A amendment does not contain new AKS-562c clinical trial data. Under SEC Regulation S-K and Staff guidance, any material development, including trial results, must be disclosed in an S-1/A if the information is known at time of filing. The absence of AKS-562c data in amendment #30 means one of two things: (a) the Cornell data is still in analysis as of mid-May 2026, or (b) analysis is complete but results are not yet sufficient to constitute a material event requiring disclosure. Either way, no public readout is imminent from the SEC channel as of this update. The most likely path to AKS-562c disclosure is now a post-pricing 8-K, once the IPO is complete and the forced-amendment window closes.
SEC Disclosure Watch: Roadshow Now LiveWith the roadshow confirmed active (S-1/A #30 + FWP filed mid-May 2026), the SEC forced-disclosure mechanism has entered its final phase. If AKS-562c trial results become known during the roadshow: before pricing, Akston must halt the offering and file a supplemental S-1/A before resuming investor meetings; they cannot price with a materially incomplete prospectus. Once the offering prices and closes, that window shifts to 8-K disclosure. Watch AXTN's SEC EDGAR filings for any last-minute S-1/A (pre-pricing) or 8-K (post-pricing). The roadshow typically runs 1-2 weeks; pricing could come as early as late May 2026.
Regulatory Watch: INAD Active · Pilot Field Study InitiatingCurrent regulatory position (July 7, 2026): AKS-562c has an active INAD with FDA-CVM and is initiating a pilot field safety and effectiveness study in client-owned cats. This is a forward step in the formal conditional approval pathway: moving from a single university clinical-setting trial to multi-site field conditions with real vet practices and client-owned animals. The Cornell trial (November 2025, ~February 2026) delivered 12-week safety data presented at ACVIM Forum June 2026. Full efficacy data (weight loss, BCS shift) has not yet been publicly disclosed. Watch channels: AXTN SEC EDGAR for 8-K filings, dvm360 and Veterinary Practice News for trade press coverage, and Cornell University College of Veterinary Medicine research page.
Akston Biosciences is a Beverly, Massachusetts-based biotechnology company developing protein-based therapeutics for both human and veterinary applications. Akston is a publicly listed company (AXTN, NYSE American) following its 2026 IPO. As of July 2026, Akston has an active INAD with FDA-CVM for AKS-562c and is initiating a pilot field safety and effectiveness study in client-owned cats: the first formal field study for a weekly injectable GLP-1 in cats. Akston is also developing a canine-specific variant of AKS-562c, making it the first dual-species GLP-1 program in veterinary pharma. Their feline candidate, AKS-562c, is a once-weekly GLP-1 Fc-fusion injection first studied at the Cornell University College of Veterinary Medicine starting November 2025.
AXTN Stock: What to Know
Ticker: AXTN. Exchange: NYSE American. Listing date: May 2, 2026. Akston Biosciences listed as a small-cap biotech with a market capitalization of approximately $100M and a $20M IPO raise. As of publication, AXTN is a thinly-traded micro-cap: typical for vet-pharma at this stage, and exposure carries the standard small-cap biotech risk profile (clinical trial outcomes, single-asset concentration risk on lead AKS-701d, regulatory uncertainty for both pipeline programs).
Watch for these material events in 8-K filings or press releases:
- •Cornell AKS-562c trial readout (Q2-Q3 2026): material event likely triggering pre-announcement and 8-K filing.
- •FDA pre-submission meetings for AKS-562c if trial succeeds. Would surface 6-12 months before IND/NADA filing.
- •AKS-701d (canine bladder cancer) updates: the lead asset, larger commercial impact than AKS-562c.
- •Follow-on financing. A $20M IPO is small; Akston will likely raise additional capital within 12-18 months. Trial success drives valuation for next round.
Editorial noteGLP-1 Pets is not a financial advice site. We surface AXTN information because Akston's public-company status changes how readers should evaluate the AKS-562c story (mandatory disclosure, pre-announcement timing, etc.). For investment decisions, consult a financial advisor and read Akston's SEC filings directly at SEC EDGAR.
Why the IPO Filing Matters
Going public meaningfully changes how readers should evaluate the AKS-562c story. Pre-IPO, Akston disclosed trial details voluntarily: useful but uncorroborated. Post-IPO:
- •Mandatory financial disclosure: Akston now reports to the SEC quarterly. Trial spending, R&D budget allocation across AKS-701d (lead) and AKS-562c (pipeline), and any material clinical updates surface in 10-Q filings.
- •Pipeline transparency: The S-1 explicitly lists AKS-562c as a disclosed pipeline asset. Hiding bad news becomes legally risky; investors will read every quarterly letter for trial progress.
- •Timeline visibility: Public companies typically pre-announce material readouts to manage market reaction. Watch for AXTN press releases and 8-K filings around the Q2-Q3 2026 readout window.
- •Capital constraint. A $20M raise is small for biotech. Akston needs trial wins to justify follow-on rounds. The Cornell readout has heightened commercial significance for them.
Akston Pipeline Beyond AKS-562c
| Asset | Indication | Stage | Notes |
|---|---|---|---|
| AKS-701d | Canine bladder cancer | Lead clinical program | Akston's lead vet asset per S-1. Different drug class from AKS-562c. |
| AKS-562c (feline) | Cat obesity (GLP-1) | INAD active · Pilot field study initiating | Once-weekly Fc-fusion injection. Cornell 70-cat trial complete; 12-week safety data presented at ACVIM Forum June 2026 (well-tolerated, no toxicity, no antidrug antibodies). Full efficacy readout pending. Now progressing to pilot field study in client-owned cats. |
| AKS-562c (canine) | Dog obesity (GLP-1) | Early development | Canine-specific variant in development per SEC S-1/A filing and dvm360. First dual-species GLP-1 program in veterinary pharma. No clinical trial timeline announced as of July 2026. |
| Other vet candidates | Various | Preclinical | S-1 lists earlier-stage protein-engineering programs without specific timelines. |
Knowing AKS-701d is the lead program changes how to read trial-readout signals: if AKS-562c data is mixed, Akston still has a primary commercial path through bladder cancer. The downside risk for AKS-562c shareholders is therefore narrower than for a single-asset company, but the upside if both succeed is correspondingly larger.
Canine GLP-1 Program: The Dog Obesity Opportunity
Beyond the feline program, Akston is developing a canine-specific version of AKS-562c targeting dog obesity: making Akston the first company with a disclosed dual-species GLP-1 program in veterinary pharma. The canine variant is expected to use the same once-weekly Fc-fusion injection platform as the feline AKS-562c, adapted for canine pharmacokinetics and dosing.
- •Separate molecule design required. Cats and dogs have different GLP-1 receptor biology, different body-weight-to-dose scaling, and different metabolic baselines. A canine-specific version is not simply a higher dose of the feline drug.
- •Timing. The canine program is in early development as of July 2026. No clinical trial initiation date has been publicly announced. Realistically, a canine GLP-1 approval would trail the feline program by 2-4 years.
- •Market size. 59% of dogs in the US are overweight or obese (APOP). At 90 million pet dogs in the US, the addressable market for canine weight-management drugs is substantially larger than the feline market, which is why every vet pharma company (Zoetis, Boehringer, Elanco) is watching this space.
- •Sources. Akston canine GLP-1 development disclosed in Akston Biosciences SEC S-1/A filing and confirmed in dvm360 trade coverage.
What Is AKS-562c?
AKS-562c is a GLP-1 receptor agonist fused to an Fc fragment: a protein engineering technique that extends drug half-life by binding to FcRn receptors that recycle proteins through the body. The same Fc-fusion approach is used in human-side drugs like dulaglutide (Trulicity). Fc-fusion typically gives once-weekly to once-monthly dosing.
Cornell Trial Design
| Element | Detail |
|---|---|
| Sponsor | Akston Biosciences |
| Site | Cornell University College of Veterinary Medicine |
| Drug | AKS-562c (GLP-1 Fc-fusion, weekly injection) |
| Target species | Domestic cats (overweight or obese) |
| Cats enrolled | 70 (option to expand to 140) |
| Primary observation | ~11 weeks |
| Trial start | November 25, 2025 |
| Treatment-phase completion (est.) | ~Mid-February 2026 (11 weeks post-start) |
| Post-completion status (as of July 7, 2026) | ACVIM Forum June 2026: 12-week safety data presented (well-tolerated, no treatment-related toxicity, no antidrug antibodies). INAD now active with FDA-CVM. Pilot field safety and effectiveness study initiating in client-owned cats. Full efficacy readout (weight/BCS) from Cornell trial still pending public disclosure. |
| Next regulatory step | Pilot field safety and effectiveness study in client-owned cats (initiating July 2026). Full efficacy readout expected via 8-K or press release. |
What to Watch For in the Readout
When Akston reports results, the field will read the data along five axes. We'll publish a full breakdown the day the news drops, but here's the framework we'll apply:
- Body weight change at 11 weeks vs control. Human-side GLP-1s deliver 5-15% weight loss in similar timeframes. A clinically meaningful feline result will likely cluster in the 4-10% range. Anything above 10% is a strong signal; below 3% would be commercially marginal.
- Body Condition Score (BCS) shift. The 9-point scale is the veterinary efficacy gold standard. A meaningful trial moves the average BCS from 7-8 down toward 5-6.
- Adverse event profile. Watch closely for hepatic enzyme elevations (ALT, ALP): feline rapid weight loss carries hepatic lipidosis risk that human GLP-1 trials don't face. Vomiting and decreased appetite are expected; severity and discontinuation rates matter.
- Injection site tolerability. Weekly subcutaneous injections in cats face owner-compliance friction. The trial likely tracks injection-site reactions, owner-reported handling difficulty, and dropouts attributable to injection burden.
- Cohort expansion decision. Akston announced a 70-cat trial with the option to expand to 140. If they expand, that's a confidence signal. If they don't, it could mean the primary cohort answered the question definitively (good sign) or fell short (bad sign).
Three Outcomes, Three Field Responses
| Scenario | What it means for the field |
|---|---|
| Strong efficacy + clean safety | Akston files for FDA approval H2 2026. Cat GLP-1 commercial launch realistic late 2027 / early 2028. Dog trial starts likely announced within 6 months. Veterinary pharma incumbents (Zoetis, Boehringer, Elanco, Merck Animal Health) accelerate their own programs. |
| Modest efficacy or safety questions | Akston runs a confirmatory trial. FDA path stretches to 2028-2029. Field watches Okava's MEOW-1 readout (summer 2026) as the deciding signal: if Okava also shows modest results, GLP-1-for-cats becomes a question of whether the regulatory pathway justifies the commercial opportunity. |
| Trial fails or significant safety concern | AKS-562c program likely shelved or pivoted. Field resets to Okava's OKV-119 (MEOW-1 trial) as the only remaining feline GLP-1 candidate. Dog programs at both companies likely delayed. Investor confidence in the entire pet GLP-1 category takes a hit. |
How AKS-562c Compares to OKV-119
| Attribute | Akston AKS-562c | Okava OKV-119 |
|---|---|---|
| Active molecule | Novel GLP-1 Fc-fusion | Exenatide (existing GLP-1) |
| Delivery | Weekly subcutaneous injection | 6-month subcutaneous implant |
| Trial site | Cornell University Vet College | Multi-site veterinary network |
| Trial cats | 70 (expandable to 140) | ≥50 |
| Trial start | November 2025 | December 2025 |
| Primary observation | ~11 weeks | 3 months + 3 mo opt |
| Expected readout | Q2-Q3 2026 | Summer 2026 |
| Repeat dosing | Weekly forever | Every 6 months |
Get the readout the day it dropsWe're tracking Akston Biosciences' investor channels, Cornell press releases, and trade press (dvm360, Veterinary Practice News). Join the trial alerts list and we'll send one email when the AKS-562c results are public.
Pipeline updates
Get notified when pet GLP-1 medications arrive.
One email when there's real news: Okava MEOW-1 results, FDA filings, the first cat & dog GLP-1 launches. Nothing else.
We never share your email. Unsubscribe in one click. Powered by Resend.
Frequently Asked Questions
Where is the Akston cat GLP-1 trial?+
The Cornell University College of Veterinary Medicine in Ithaca, New York. The trial enrolls 70 cats with the option to expand to 140.
How does AKS-562c differ from Okava's OKV-119?+
AKS-562c is a novel GLP-1 Fc-fusion delivered as weekly injections. OKV-119 is an exenatide-releasing implant lasting roughly 6 months. Different molecules, different delivery formats.
When will AKS-562c be available?+
Akston presented 12-week safety and tolerability data at the 2026 ACVIM Forum (June 2026): well-tolerated in felines, no treatment-related toxicity, no antidrug antibodies detected. Full efficacy data (weight loss, BCS shift) was not disclosed at ACVIM. That readout remains pending. With the IPO now closed, post-IPO 8-K is the expected disclosure channel. FDA submission timeline depends on full trial results. Realistic earliest commercial launch for cats: 2028-2029.
Has the Cornell trial finished yet?+
The treatment phase of the primary cohort most likely concluded in mid-February 2026, based on the announced ~11-week observation window from the November 25, 2025 trial initiation. In June 2026, Akston presented 12-week safety and tolerability data at the 2026 ACVIM Forum. Confirming the treatment phase is complete and safety analysis is done. However, full efficacy data (weight loss and BCS endpoints) has not been publicly disclosed as of June 26, 2026. The complete efficacy readout is expected via post-IPO 8-K filing.
Is Akston Biosciences a public company?+
Yes. Akston Biosciences (AXTN, NYSE American) completed its IPO: originally targeting ~$20M at approximately $100M market cap, in late May / early June 2026. The company is now fully public and subject to SEC quarterly disclosure requirements. Future AKS-562c updates, including the full efficacy readout, will surface via 8-K filings. The AXTN EDGAR page is the primary channel to monitor for material AKS-562c disclosures.
What do the S-1/A amendment #30 and Free Writing Prospectus filings mean?+
Akston filed S-1/A amendment #30 and a companion Free Writing Prospectus simultaneously in mid-May 2026. This paired filing pattern is the standard SEC sequence that confirms an IPO roadshow is actively underway. Institutional investor meetings are in progress with underwriter ThinkEquity. Importantly, the amendment contained no new AKS-562c clinical trial data. Under SEC rules, material clinical results would have been required in the amendment if known at time of filing. Their absence confirms the Cornell data had not reached management as of mid-May 2026. Pricing is expected in late May 2026; AKS-562c results will most likely surface via 8-K filing after the IPO closes.
What is AKS-701d?+
AKS-701d is Akston Biosciences' lead clinical program: a veterinary biologic for canine bladder cancer. It's separate from AKS-562c (the cat GLP-1 candidate) and is the primary commercial focus per the S-1 filing.
What is an INAD and why does it matter for AKS-562c?+
An INAD (Investigational New Animal Drug) is the FDA Center for Veterinary Medicine's equivalent of the human IND (Investigational New Drug) application. An active INAD means FDA has accepted Akston's application to clinically investigate AKS-562c and the company can conduct studies under FDA oversight. It is a prerequisite for conducting formal clinical trials. Including the pilot field study, and is a necessary step on the conditional approval pathway toward a New Animal Drug Application (NADA). Having an active INAD is a regulatory milestone that confirms AKS-562c is now inside the formal FDA review process, not simply a lab-based academic experiment.
What is a pilot field study and how does it differ from the Cornell trial?+
A pilot field study is conducted in client-owned animals at real veterinary practices (field conditions), testing both safety AND effectiveness together. The Cornell trial was a controlled academic clinical setting: a single site with enrolled research cats and a defined observation protocol. A pilot field study is broader: multiple real-world vet practices, owner-reported compliance data, and effectiveness outcomes measured alongside safety. Under FDA-CVM's conditional approval pathway, a successful pilot field study typically supports a pivotal effectiveness study or a conditional approval application (XCA). The initiation of the pilot field study is therefore a significant step forward from the Cornell trial.
Is Akston developing a GLP-1 drug for dogs?+
Yes. Akston has disclosed development of a canine-specific version of AKS-562c: a once-weekly GLP-1 Fc-fusion injection targeting dog obesity, making Akston the first company with a disclosed dual-species GLP-1 program in veterinary pharma. As of July 2026, the canine program is in early development with no announced clinical trial timeline. The feline AKS-562c program (INAD active, pilot field study initiating) is considerably further advanced. Sources: Akston Biosciences SEC S-1/A filing and dvm360.
Related
Veterinary disclaimer:This article is for informational purposes only and does not constitute veterinary advice. Always consult a licensed veterinarian before changing your pet's diet, exercise routine, or medication. Information is current as of the publication date but pet pharmaceutical and food formulation details may change.
Looking for human GLP-1 medications instead?
Visit GLP-1 Picks → 42 verified telehealth providers